scholarly journals Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression

2008 ◽  
Vol 83 (4) ◽  
pp. 1049-1059 ◽  
Author(s):  
N. Larmonier ◽  
J. Cantrell ◽  
C. LaCasse ◽  
G. Li ◽  
N. Janikashvili ◽  
...  
Keyword(s):  
T Cell ◽  
Tumor Cell ◽  
Regulatory T Cell ◽  
Antigen Presenting Cells ◽  
Cell Lysate ◽  
T Cell Suppression ◽  
Tumor Cell Lysate ◽  
Cell Suppression ◽  
Antigen Presenting

scholarly journals Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis

Rheumatology ◽  
2015 ◽  
Vol 55 (4) ◽  
pp. 710-720 ◽  
Author(s):  
Michael Bonelli ◽  
Lisa Göschl ◽  
Stephan Blüml ◽  
Thomas Karonitsch ◽  
Kiyoshi Hirahara ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
T Cell ◽  
Regulatory T Cell ◽  
Cell Apoptosis ◽  
T Cell Apoptosis ◽  
T Cell Suppression ◽  
Cell Suppression

Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10

2006 ◽  
Vol 56 (1) ◽  
pp. 48-59 ◽  
Author(s):  
Nicolas Larmonier ◽  
Marilyn Marron ◽  
Yi Zeng ◽  
Jessica Cantrell ◽  
Angela Romanoski ◽  
...  
Keyword(s):  
T Cell ◽  
Dendritic Cell ◽  
Regulatory T Cell ◽  
Cell Function ◽  
Dendritic Cell Function ◽  
T Cell Suppression ◽  
Cell Suppression

scholarly journals Regulatory T Cell Suppression Is Potentiated by Target T Cells in a Cell Contact, IL-35- and IL-10-Dependent Manner

2009 ◽  
Vol 182 (10) ◽  
pp. 6121-6128 ◽  
Author(s):  
Lauren W. Collison ◽  
Meenu R. Pillai ◽  
Vandana Chaturvedi ◽  
Dario A. A. Vignali
Keyword(s):  
T Cells ◽  
T Cell ◽  
Regulatory T Cell ◽  
Cell Contact ◽  
Dependent Manner ◽  
T Cell Suppression ◽  
A Cell ◽  
Cell Suppression

scholarly journals Cutting Edge: The Natural Ligand for Glucocorticoid-Induced TNF Receptor-Related Protein Abrogates Regulatory T Cell Suppression

2004 ◽  
Vol 172 (10) ◽  
pp. 5823-5827 ◽  
Author(s):  
Hong-bin Ji ◽  
Gongxian Liao ◽  
William A. Faubion ◽  
Ana C. Abadía-Molina ◽  
Cristina Cozzo ◽  
...  
Keyword(s):  
T Cell ◽  
Regulatory T Cell ◽  
Cutting Edge ◽  
Tnf Receptor ◽  
Related Protein ◽  
Natural Ligand ◽  
T Cell Suppression ◽  
Cell Suppression

Poorex vivoinduction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma

2006 ◽  
Vol 47 (7) ◽  
pp. 1340-1347 ◽  
Author(s):  
Laurent Garderet ◽  
Christelle Mazurier ◽  
Catherine Pellat-Deceunynck ◽  
Abdul Karim ◽  
Bruno Baudin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Dendritic Cells ◽  
T Cell ◽  
Tumor Cell ◽  
T Cell Responses ◽  
Cell Responses ◽  
Cell Lysate ◽  
Tumor Cell Lysate

scholarly journals PKHB1 Tumor Cell Lysate Induces Antitumor Immune System Stimulation and Tumor Regression in Syngeneic Mice with Tumoral T Lymphoblasts

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Ana Carolina Martínez-Torres ◽  
Kenny Misael Calvillo-Rodríguez ◽  
Ashanti Concepción Uscanga-Palomeque ◽  
Luis Gómez-Morales ◽  
Rodolfo Mendoza-Reveles ◽  
...  
Keyword(s):  
Cell Death ◽  
T Cell ◽  
Tumor Cell ◽  
Immune Tolerance ◽  
Tumor Regression ◽  
Ex Vivo ◽  
Cell Lysate ◽  
Hematological Cancers ◽  
Tumor Cell Lysate

Acute lymphocytic leukemia (ALL) is the most common pediatric cancer. Currently, treatment options for patients with relapsed and refractory ALL mostly rely on immunotherapies. However, hematological cancers are commonly associated with a low immunogenicity and immune tolerance, which may contribute to leukemia relapse and the difficulties associated with the development of effective immunotherapies against this disease. We recently demonstrated that PKHB1, a TSP1-derived CD47 agonist peptide, induces immunogenic cell death (ICD) in T cell ALL (T-ALL). Cell death induced by PKHB1 on T-ALL cell lines and their homologous murine, L5178Y-R (T-murine tumor lymphoblast cell line), induced damage-associated molecular patterns (DAMPs) exposure and release. Additionally, a prophylactic vaccination with PKHB1-treated L5178Y-R cells prevented tumor establishment in vivo in all the cases. Due to the immunogenic potential of PKHB1-treated cells, in this study we assessed their ability to induce antitumor immune responses ex vivo and in vivo in an established tumor. We first confirmed the selectivity of cell death induced by PKBH1 in tumor L5178Y-R cells and observed that calreticulin exposure increased when cell death increased. Then, we found that the tumor cell lysate (TCL) obtained from PKHB1-treated L5178YR tumor cells (PKHB1-TCL) was able to induce, ex vivo, dendritic cells maturation, cytokine production, and T cell antitumor responses. Finally, our results show that in vivo, PKHB1-TCL treatment induces tumor regression in syngeneic mice transplanted with L5178Y-R cells, increasing their overall survival and protecting them from further tumor establishment after tumor rechallenge. Altogether our results highlight the immunogenicity of the cell death induced by PKHB1 activation of CD47 as a potential therapeutic tool to overcome the low immunogenicity and immune tolerance in T-ALL.

scholarly journals Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine

Vaccines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 25 ◽  
Author(s):  
Caroline Boudousquié ◽  
Valérie Boand ◽  
Emilie Lingre ◽  
Laeticia Dutoit ◽  
Klara Balint ◽  
...  
Keyword(s):  
T Cell ◽  
Dendritic Cell ◽  
Tumor Cell ◽  
Manufacturing Process ◽  
Tumor Lysate ◽  
Cell Lysate ◽  
Cell Factories ◽  
Dc Vaccine ◽  
Dc Vaccines ◽  
Tumor Cell Lysate

With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here, we describe the development and optimization of a Good Manufacturing Practice (GMP)-compliant manufacturing process based on tumor lysate as a tumor antigen source for the production of an oxidized tumor cell lysate loaded DC (OC-DC) vaccine. The manufacturing process required one day for lysate preparation and six days for OC-DC vaccine production. Tumor lysate production was standardized based on an optimal tumor digestion protocol and the immunogenicity was improved through oxidation using hypochloric acid prior to freeze-thaw cycles resulting in the oxidized tumor cell lysate (OC-L). Next, monocytes were selected using the CliniMACS prodigy closed system and were placed in culture in cell factories in the presence of IL-4 and GM-CSF. Immature DCs were loaded with OC-L and matured using MPLA-IFNγ. After assessing the functionality of the OC-DC cells (IL12p70 secretion and COSTIM assay), the OC-DC vaccine was cryopreserved in multiple doses for single use. Finally, the stability of the formulated doses was tested and validated. We believe this GMP-compliant DC vaccine manufacturing process will facilitate access of patients to personalized DC vaccines, and allow for multi-center clinical trials.

Sign in / Sign up

Export Citation Format

Share Document